Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.08
33.53
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co Ltd
Accrued Liabilities
Shenzhen Kangtai Biological Products Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shenzhen Kangtai Biological Products Co Ltd
SZSE:300601
|
Accrued Liabilities
¥68.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥2.6B
|
CAGR 3-Years
49%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Accrued Liabilities
¥268.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Accrued Liabilities
¥164.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
19%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Accrued Liabilities
¥325.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
21%
|
CAGR 10-Years
45%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Accrued Liabilities
¥116.1m
|
CAGR 3-Years
52%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Shenzhen Kangtai Biological Products Co Ltd
Glance View
Shenzhen Kangtai Biological Products Co., Ltd. engages in the manufacture, sale, and research and development of human vaccines. The company is headquartered in Shenzhen, Guangdong and currently employs 2,445 full-time employees. The company went IPO on 2017-02-07. is a China-based company and mainly engaged in research and development, manufacture and sale of vaccine. The main products of the company are recombinant hepatitis B virus, haemophilus influenzae type b combined vaccine, measles rubella combined attenuated live vaccine, non-cell Bai Bai Po haemophilus influenzae combined vaccine and other products. The firm operates its businesses primary in domestic market.
See Also
What is Shenzhen Kangtai Biological Products Co Ltd's Accrued Liabilities?
Accrued Liabilities
68.6m
CNY
Based on the financial report for Jun 30, 2024, Shenzhen Kangtai Biological Products Co Ltd's Accrued Liabilities amounts to 68.6m CNY.
What is Shenzhen Kangtai Biological Products Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
29%
Over the last year, the Accrued Liabilities growth was 15%. The average annual Accrued Liabilities growth rates for Shenzhen Kangtai Biological Products Co Ltd have been 17% over the past three years , 29% over the past five years .
You don't have any saved screeners yet
